期刊文献+

原发性膀胱恶性淋巴瘤1例报告并文献复习

Primary malignant lymphoma of the bladder:one case report and literature review
原文传递
导出
摘要 目的:探讨原发性膀胱恶性淋巴瘤(PMLB)的临床和病理特点,提高对该病的认识和诊治水平。方法:回顾性分析1例PMLB患者的临床病理资料,复习相关文献并讨论其发病特点、影像学特征、治疗及预后。结果:患者行经尿道膀胱肿瘤切检术,术后病理检查确诊为PMLB(弥漫性大B细胞型)。术后给予R-CHOP方案化疗4个疗程,患者一般情况良好,已存活6个月,目前仍在随访中。结论:PMLB是一种罕见的膀胱肿瘤,组织病理学检查是确诊该病的"金标准"。PMLB的最佳治疗方式及预后尚不明确,以化疗为主,辅以放疗、手术治疗的综合治疗临床应用较广泛。针对局部晚期或高恶性度的肿瘤,单纯化疗通常疗效满意。 Objective:To discuss the clinical manifestation and pathology of primary malignant lymphoma of the bladder(PMLB)and to improve the early diagnosis of PMLB.Method:Clinical and pathologic data of one patient with PMLB were retrospectively summarized and relevant literature at home and abroad was reviewed.The clinical and radiological signs were described.Result:The pathological diagnosis was PMLB(diffuse large B-cell lymphoma).Four cycles of R-CHOP regimen were given and the patient maintained well after six months of follow-up period.Conclusion:PMLB is rare and the diagnosis is based exclusively on histological examination.The treatment of PMLB is not well defined and the prognosis remains unknown.Chemotherapy,radiotherapy and surgery either alone or in combination are considered to be therapeutic options.However,chemotherapy alone is recommended for locally advanced tumors or high grade.
出处 《临床泌尿外科杂志》 2014年第8期718-720,共3页 Journal of Clinical Urology
基金 天津市科委重点项目(编号12JCZDJC23700)
关键词 膀胱肿瘤 恶性淋巴瘤 临床特点 治疗 bladder neoplasms malignant lymphoma clinical features therapy
  • 相关文献

参考文献15

  • 1张磊,王晓雄,许勇.原发性膀胱恶性淋巴瘤[J].军医进修学院学报,2000,21(3):172-174. 被引量:3
  • 2Antunes A A,Nesrallah L J,Srougi M.Non-Hodgkin lymphoma of the bladder[J].Int Braz J Urol,2004,30(6):499-501.
  • 3Bates A W,Norton A J,Baithun S I.Malignant lymphoma of the urinary bladder:a clinicopathological study of 11cases[J].J Clin Pathol,2000,53(6):458-461.
  • 4杨宁宁,王欣.弥漫大B细胞淋巴瘤治疗的临床研究进展[J].临床血液学杂志,2012,25(6):753-756. 被引量:5
  • 5Fernández Aceero M J,Martín Rodilla C,López García-Asenjo J,et al.Primary malignant lymphoma of the bladder:Report of three cases[J].Pathol Res Pract,1996,192(2):160-163;discussion 164-165.
  • 6Simpson R H,Bridger J E,Anthony P P,et al.Malignant lymphoma of the lower urinary tract:A clinicopathological study with review of the literature[J].Br J Urol,1990,65(3):254-260.
  • 7Tasu J P,Geffroy D,Rocher L,et al.Primary malignant lymphoma of the urinary bladder:report of three cases and review of the literature[J].Eur Radiol,2000,10(8):1261-1264.
  • 8Mahfoud T,Tanz R,Mesmoudi M,et al.Primary non-Hodgkin's lymphoma of the bladder:case report and literature review[J].Pan Afr Med J,2013,15:136.
  • 9Peyromaure M,Van Glabeke E,Leblond V,et al.Primary lymphoma of the bladder[J].Prog Urol,2000,10(6):1208-1211.
  • 10Kempton C L,Kurtin P J,Inwards D J,et al.Malignant lymphoma of the bladder:evidence from 36cases that low-grade lymphoma of the MALT-type is the most common primary bladder lymphoma[J].Am J Surg Pathol,1997,21(11):1324-1333.

二级参考文献50

  • 1Harris NL, Jaffe ES, Diebold J, et al. Lymphoma classification--from controversy to consensus: the R. E. A. L. and WHO classification of lymphoid neoplasms. Ann Oncol, 2000,11 Suppl 1:3-10.
  • 2Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature,2000,403(6769) :503-511.
  • 3Rosenwald A,Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med, 2002,346 (25):1937-1947.
  • 4Wright G, Tan B, Rosenwald A, et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA, 2003,100 (17) :9991-9996.
  • 5Houldsworth J, Olshen AB, Cattoretti G, et al. Relationship between REL amplification, REL function, and clinical and biologic features in diffuse large B- cell lymphomas. Blood, 2004,103 ( 5 ) : 1862-1868.
  • 6Lam LT, Davis RE, Pierce J, et al. Small molecule inhibitors of Ikappa B kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res,2005,11 (1) :28-40.
  • 7Al Kuraya K, Siraj AK, Bavi P, et al. High throughput tissue microarray analysis of FHIT expression in diffuse large cell B-cell lymphoma from Saudi Arabia. Mod Pathol, 2006,19(8) :1124-1129.
  • 8Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med, 2002,8(1 ) :68-74.
  • 9Poulsen CB, Borup R, Nielsen FC, et al. Microarray-based classification of diffuse large B-cell lymphoma. Eur J Haematol, 2005,74 (6) :453-465.
  • 10Viseo C, Canal F, Parolini C, et al. The impact of P53 and P21( waf1 ) expression on the survival of patients with the germinal center phenotype of diffuse large B-cell lymphoma. Haematologica, 2006,91(5) :687-690.

共引文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部